首页 | 官方网站   微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   46813篇
  免费   3111篇
  国内免费   912篇
医药卫生   50836篇
  2023年   382篇
  2022年   717篇
  2021年   1627篇
  2020年   1031篇
  2019年   1139篇
  2018年   1283篇
  2017年   1052篇
  2016年   1090篇
  2015年   1407篇
  2014年   1845篇
  2013年   2266篇
  2012年   2945篇
  2011年   2992篇
  2010年   1801篇
  2009年   1642篇
  2008年   2529篇
  2007年   2563篇
  2006年   2380篇
  2005年   2250篇
  2004年   2040篇
  2003年   1781篇
  2002年   1584篇
  2001年   1439篇
  2000年   1363篇
  1999年   1259篇
  1998年   460篇
  1997年   350篇
  1996年   370篇
  1995年   282篇
  1994年   258篇
  1993年   213篇
  1992年   691篇
  1991年   576篇
  1990年   542篇
  1989年   558篇
  1988年   463篇
  1987年   430篇
  1986年   410篇
  1985年   320篇
  1984年   267篇
  1983年   220篇
  1982年   123篇
  1979年   217篇
  1978年   133篇
  1977年   117篇
  1974年   129篇
  1973年   128篇
  1972年   122篇
  1971年   112篇
  1969年   105篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
11.
目的评估血肌酐和尿常规的常规检测基础上联合血清胱抑素C和尿微量白蛋白检测在人类免疫缺陷病毒(HIV)感染者肾功能损伤检测中的应用价值。 方法以2019年2~5月于首都医科大学附属北京地坛医院感染一科住院的169例HIV感染者为研究对象,完善其尿常规、尿微量白蛋白、血肌酐、血清胱抑素C检测;分析尿蛋白及尿微量白蛋白的阳性检出率及其差异,血肌酐升高及血清胱抑素C升高的比例及其差异。计算应用替诺福韦酯(TDF)及合并丙型肝炎、高血压、糖尿病、肿瘤的肾功能损伤的相对危险度。 结果169例HIV感染者中尿常规示尿蛋白阳性者5例(3.0%),尿微量白蛋白升高者17例(10.1%),两者阳性检出率差异具有统计学意义(χ2 = 5.9、P = 0.007)。血肌酐升高者10例(5.9%),血清胱抑素C升高者20例(11.8%),两者阳性检出率差异具有统计学意义(χ2 = 3.0、P = 0.042)。在尿常规和血肌酐检测的基础上联合检测尿微量白蛋白和血清胱抑素C的总体阳性检出率为49例(30.0%)。CD4+ T淋巴细胞计数< 200个/μl与≥ 200个/μl组患者血清胱抑素C水平分别为0.94(0.83,1.05)mg/L、0.85(0.77,0.95)mg/L,差异具有统计学意义(Z =-3.02、P = 0.003)。应用TDF及合并丙型肝炎、高血压、糖尿病、肿瘤的肾功能损伤的相对危险度分别为1.1、1.5、1.9、2.2和1.4。 结论HIV感染者中,单纯以尿常规为依据评估有无蛋白尿,以血肌酐水平为依据评估肾小球滤过功能会低估肾功能损伤的患病率。在常规检测血肌酐和尿常规的基础上联合检测血清胱抑素C和尿微量白蛋白在提高HIV感染者肾功能损伤检出率方面具有重要的应用价值。低CD4+ T淋巴细胞计数、应用TDF及合并丙型肝炎、高血压、糖尿病、肿瘤均为肾功能损伤的危险因素。  相似文献   
12.
To evaluate the changes in alveolar contour after guided bone regeneration (GBR) with two different combinations of biomaterials in dehiscence defects arou  相似文献   
13.
14.
15.
16.
17.

Introduction/Hypothesis

Recruitment of participants into phase 1 vaccine clinical trials can be challenging since these vaccines have not been used in humans and there is no perceived benefit to the participant. Occasionally, as was the case with a phase 1 clinical trial of an Ebola vaccine in Halifax, Canada, during the 2014–2016 West African Ebola virus outbreak, recruitment is less difficult. In this study, we explored the motivations of participants in two phase 1 vaccine trials that were concurrently enrolling at the same centre and compared the motivations of participants in a high-profile phase 1 Ebola vaccine trial to those in a less high-profile phase 1 adjuvanted seasonal influenza vaccine study.

Methods

An online survey which included participants’ prior experience with clinical trials, motivations to participate (including financial incentives), and demographic information was developed to examine the motivations of healthy participants in two phase 1 clinical vaccine trials conducted at the Canadian Center for Vaccinology in Halifax, Nova Scotia. Participants were invited via email to complete the online survey. Readability and clarity were assessed through pilot testing.

Results

A total of 49 (55.7%) of 88 participants of the two studies completed the survey (22 [55%] of 40 participants from the Ebola vaccine study and 27 [56.3%] of 48 from the adjuvanted influenza vaccine study). Motivations that were most frequently ranked among participants' top three in both trials were (1) wanting to contribute to the health of others, (2) wanting to participate in something important, (3) wanting to contribute to the advancement of science, and (4) wanting to receive an incentive such as money or a tablet.

Conclusions/Recommendations

Although media attention and financial compensation were more often cited by Ebola vaccine trial participants as a reason to participate, both altruistic and self-interested factors were important motivations for participants in their decision to participate in a phase 1 vaccine clinical trial.  相似文献   
18.
19.

Background

Rosacea is a chronic inflammatory skin condition whose etiology has been linked to mast cells and the antimicrobial peptide cathelicidin LL-37. Individuals with refractory disease have demonstrated clinical benefit with periodic injections of onabotulinum toxin, but the mechanism of action is unknown.

Objectives

To investigate the molecular mechanism by which botulinum toxin improves rosacea lesions.

Methods

Primary human and murine mast cells were pretreated with onabotulinum toxin A or B or control. Mast cell degranulation was evaluated by β-hexosaminidase activity. Expression of botulinum toxin receptor Sv2 was measured by qPCR. The presence of SNAP-25 and VAMP2 was established by immunofluorescence. In vivo rosacea model was established by intradermally injecting LL-37 with or without onabotulinum toxin A pretreatment. Mast cell degranulation was assessed in vivo by histologic counts. Rosacea biomarkers were analyzed by qPCR of mouse skin sections.

Results

Onabotulinum toxin A and B inhibited compound 48/80-induced degranulation of both human and murine mast cells. Expression of Sv2 was established in mouse mast cells. Onabotulinum toxin A and B increased cleaved SNAP-25 and decreased VAMP2 staining in mast cells respectively. In mice, injection of onabotulinum toxin A significantly reduced LL-37-induced skin erythema, mast cell degranulation, and mRNA expression of rosacea biomarkers.

Conclusions

These findings suggest that onabotulinum toxin reduces rosacea-associated skin inflammation by directly inhibiting mast cell degranulation. Periodic applications of onabotulinum toxin may be an effective therapy for refractory rosacea and deserves further study.  相似文献   
20.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号